Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 8 holding rows worth $322,862,731.

Accession
0000899140-25-000321
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 8 entries on the cover page, a total value of $322,862,731 stated on the cover page (in dollars after the unit check, H1), rows summing to $322,862,731 with VALUE read as dollars as filed, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
INNOVIVA INC45781M101COM7,277,000$126,255,950dollars as filed
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK16,390,000$72,607,700dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM309,116$42,194,334dollars as filed
CYTOKINETICS INC23282W605COM NEW833,799$39,221,905dollars as filed
Gilead Sciences,Inc.375558103COM262,080$24,208,330dollars as filed
AMARIN CORP PLC023111206SPONS ADR NEW24,850,623$12,052,552dollars as filed
LANTHEUS HLDGS INC516544103COM63,000$5,635,980dollars as filed
VOR BIOPHARMA INC929033108COM618,000$685,980dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000899140-25-000321this filing2025-02-14acceptance time not in the bulk data set